Metastatic Breast Cancer, Mutation, Point
Conditions
Brief summary
The use of circulating tumor DNA (ctDNA) as a noninvasive test for breast cancer monitoring throughout the course of the disease
Detailed description
The concentrations of the cell free DNA (cfDNA) and somatic mutations in circulating tumor DNA (ctDNA) in serial samples correlate with the number of days of the progression-free period and with the overall survival.
Interventions
None listed
Sponsors
Universidad de Costa Rica
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Metastatic breast cancer before the start of chemotherapeutic treatment
Exclusion criteria
* Patients with incomplete clinical records
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of circulating free DNA (cfDNA) concentration (in ng/uL) obtained from peripheral blood (liquid biopsy). | 12 months | Samples will be analyze with Real time PCR and fluorometric assay and compare with overall survival |
| Number of somatic mutation findings in circulating free DNA (cfDNA) obtained from peripheral blood (liquid biopsy) | 12 months | Samples will be analyze with targeted NGS sequencing panel |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Estrogen Receptor (ER), Progesterone Receptor (PR), Human Epidermal Growth Factor Receptor 2 (HER2) status | 24 months | ER, PR, HER2 status |
| Overall survival of participant | 24 months | Overall survival of participant |
| Cancer stage of participant | 24 months | Cancer stage of participant |
Countries
Costa Rica
Contacts
Primary ContactRicardo Chinchilla
Backup ContactAllan Ramos, Msc.
Outcome results
None listed